Cardiol Therapeutics (CRDL)
(Delayed Data from NSDQ)
$1.99 USD
+0.01 (0.51%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.98 -0.01 (-0.50%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CRDL 1.99 +0.01(0.51%)
Will CRDL be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRDL
Cardiol Therapeutics (CRDL) Upgraded to Buy: Here's Why
5 Small Drug Stocks to Buy From a Recovering Industry
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Other News for CRDL
Cordel Group confirms Natasha Dinneen's appointment as CFO
Cordel Group Announces New CFO and Board Changes
Cardiol Therapeutics Inc (CRDL) Shares Up 8.74% on Sep 9
Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024